![Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS | Business Wire Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS | Business Wire](https://mms.businesswire.com/media/20201209005097/en/845277/4/4788158_4788053_120920_-_PD3-03_Holmes_ExteNET_OS_SABCS_2020_poster_FINAL.jpg)
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS | Business Wire
![Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha](https://static3.seekingalpha.com/uploads/sa_presentations/448/67448/slides/1.jpg?1615833116)
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
![Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review](https://www.pharmaceutical-business-review.com/wp-content/uploads/2019/04/medic-563423_960_720.jpg)
Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review
Former Puma Biotechnology exec is accused of making $1.2 million from insider trading - Los Angeles Times
In the wake of Puma Biotechnology, Inc.'s (NASDAQ:PBYI) latest US$17m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St News
![Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America](https://www.pint-pharma.com/images/st_metanic/blog/blog-2.png)
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
![Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib - Pharmaceutical Business review Puma Biotechnology expands cohorts in phase II SUMMIT trial of Neratinib - Pharmaceutical Business review](https://www.pharmaceutical-business-review.com/wp-content/uploads/2019/04/tumor.jpg)